Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Jul 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first half financial results | Download |
02 Jul 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the second quarter of 2018 | Download |
22 Jun 2018 | Información sobre dividendos | The Company informs about the dividends payment | Download |
12 Jun 2018 | Otros sobre negocio y situación financiera | Corporate presentation update | Download |
29 May 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |